



US 20210310008A1

(19) **United States**(12) **Patent Application Publication**
Parker et al.(10) **Pub. No.: US 2021/0310008 A1**(43) **Pub. Date: Oct. 7, 2021**(54) **PARN AS A BIOMARKER AND
THERAPEUTIC TARGET***A61K 31/704* (2006.01)*A61K 31/7125* (2006.01)*A61P 35/00* (2006.01)(71) Applicant: **The Regents of the University of
Colorado, a body corporate, Denver,
CO (US)**(52) **U.S. Cl.**CPC *C12N 15/1137* (2013.01); *C12Q 1/6886*
(2013.01); *A61K 31/704* (2013.01); *A61K*
31/7125 (2013.01); *C12Q 2600/158* (2013.01);
C12N 2310/11 (2013.01); *C12N 2320/31*
(2013.01); *C12N 2310/315* (2013.01); *A61P*
35/00 (2018.01)(21) Appl. No.: **17/266,502**(22) PCT Filed: **Aug. 7, 2019**(86) PCT No.: **PCT/US19/45540**

§ 371 (c)(1),

(2) Date: **Feb. 5, 2021****Related U.S. Application Data**(60) Provisional application No. 62/715,688, filed on Aug.
7, 2018.**Publication Classification**(51) **Int. Cl.***C12N 15/113* (2006.01)*C12Q 1/6886* (2006.01)

(57)

ABSTRACT

Increased PARN as an indicator of a cancer involving loss or reduction in p53 function. PARN is also provided as a therapeutic target for treating a cancer involving loss or reduction in p53 function. Methods of treating a subject having a cancer involving loss or reduction in p53 function based on the level of PARN in a test sample obtained from the subject and administering an effective amount of a PARN inhibitor, alone or in conjunction with another chemotherapeutic agent, to the subject to treat the cancer.

Specification includes a Sequence Listing.